> Diabetes Research > Prostate Cancer Therapy May double DM Risk

Prostate Cancer Therapy May double DM Risk

A recent study conducted by the scientists of the Philippine General Hospital shows that patients undergoing treatment for prostate cancer may increase diabetes risk.

In a study of 74 males treated for prostate cancer, 42 percent received androgen deprivation therapy, while the remaining 19 did not. According to the result, only those who received such therapy had developed type 2 diabetes considering that both groups had similar risk profiles for such disease.

The androgen deprivation therapy refers to the reduction of androgen (male reproductive hormone) levels through a hormone that obstructs its production. This therapy often makes prostate cancers shrink or grow more slowly.

But, studies on the treatment show that it has various side effects that include erectile dysfunction, loss of libido, weight gain, fatigue, decreased penis size, and depression. It has also been proposed that it can be a factor in the onset of cardiovascular disease and diabetes.

The researchers added that the hormone therapy group had a higher frequency of metabolic syndrome – “the cluster of conditions that is often the precursor to the onset of diabetes.”

The PGH study lasted from 2004 to 2010. Its findings were delivered at ENDO 2011, the 93rd annual meeting of the Endocrine Society.

Related terms:

Related Posts:

  • No Related Posts

» Tags: , , ,

Related terms:

Leave a Reply

Your email address will not be published. Required fields are marked *